Company Filing History:
Years Active: 1997-2000
Title: Gerd J. Steffens: Innovator in Fibrinolytic Proteins
Introduction
Gerd J. Steffens is a prominent inventor based in Aachen, Germany. He has made significant contributions to the field of biochemistry, particularly in the development of innovative proteins with therapeutic applications. With a total of 5 patents, his work focuses on enhancing medical treatments through genetic engineering.
Latest Patents
Steffens' latest patents include groundbreaking inventions such as chimeric proteins that possess fibrinolytic and thrombin-inhibiting properties. These chimeric proteins are designed with a plasminogen-activating amino acid sequence linked to a thrombin-inhibiting amino acid sequence at the C-terminal end. Another notable patent involves proteins that have fibrinolytic and coagulation-inhibiting properties. These proteins are engineered to link at the N- and/or C-terminal end of the plasminogen-activating amino acid sequence to a thrombin- or factor Xa-inhibiting amino acid sequence. The proteins produced through genetic engineering are particularly useful as thrombolytic agents.
Career Highlights
Gerd J. Steffens is associated with Grünenthal GmbH, a company known for its focus on innovative pharmaceutical solutions. His work at Grünenthal has allowed him to explore the potential of his inventions in real-world applications, contributing to advancements in medical treatments.
Collaborations
Steffens collaborates with esteemed colleagues such as Stephan Wnendt and Regina Heinzel-Wieland. Their combined expertise enhances the research and development efforts within their field.
Conclusion
Gerd J. Steffens stands out as a key figure in the innovation of fibrinolytic proteins, with a strong portfolio of patents that reflect his dedication to advancing medical science. His contributions continue to pave the way for new therapeutic options in the healthcare industry.